Growing Market Presence Aveva Drug Delivery Systems has experienced significant growth through recent acquisitions, including New Vision Pharmaceuticals and KriGen Pharmaceuticals, expanding its manufacturing capabilities and product portfolio in complex sterile and transdermal formulations.
Recent Facility Expansions The company's investment in FDA-registered manufacturing facilities and the relocation of its headquarters to Miramar, Florida, indicates an ongoing commitment to expanding production capacity and improving supply chain efficiency, offering opportunities for partners seeking reliable manufacturing support.
Innovation in Transdermal Delivery Launching advanced transdermal products like the generic Buprenorphine Transdermal System demonstrates Aveva's expertise in controlled-release drug delivery, presenting potential collaborations for companies focusing on high-demand transdermal and complex pharmaceutical solutions.
Financial Strength and Market Reach With revenues estimated between $100 million and $250 million, Aveva operates in a substantial market segment, offering a stable platform for partnerships in pharmaceutical manufacturing, R&D, and product commercialization opportunities.
Leverage Technological Capabilities Utilizing a broad tech stack including MySQL, JD Edwards, and TrackWise, the company emphasizes quality and efficient process management, which can be advantageous for technology providers aiming to integrate or enhance pharmaceutical manufacturing infrastructure.